JP2014532412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532412A5 JP2014532412A5 JP2014539029A JP2014539029A JP2014532412A5 JP 2014532412 A5 JP2014532412 A5 JP 2014532412A5 JP 2014539029 A JP2014539029 A JP 2014539029A JP 2014539029 A JP2014539029 A JP 2014539029A JP 2014532412 A5 JP2014532412 A5 JP 2014532412A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- polypeptide
- mhc
- mouse
- microglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 170
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 166
- 229920001184 polypeptide Polymers 0.000 claims description 165
- 239000002773 nucleotide Substances 0.000 claims description 96
- 125000003729 nucleotide group Chemical group 0.000 claims description 96
- 241000283984 Rodentia Species 0.000 claims description 67
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 45
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 37
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 25
- 101000937526 Mus musculus Beta-2-microglobulin Proteins 0.000 claims description 23
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 15
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 15
- 230000001086 cytosolic effect Effects 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 108700024394 Exon Proteins 0.000 claims description 9
- 102000047279 human B2M Human genes 0.000 claims description 9
- 108700043516 mouse H-2Kb Proteins 0.000 claims description 9
- 102000011786 HLA-A Antigens Human genes 0.000 claims description 8
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 3
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 3
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 3
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 3
- 210000001161 mammalian embryo Anatomy 0.000 claims description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 25
- 210000004027 cell Anatomy 0.000 claims 7
- 230000003013 cytotoxicity Effects 0.000 claims 3
- 231100000135 cytotoxicity Toxicity 0.000 claims 3
- 241001529936 Murinae Species 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552587P | 2011-10-28 | 2011-10-28 | |
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US61/552,587 | 2011-10-28 | ||
| US61/552,582 | 2011-10-28 | ||
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| US61/700,908 | 2012-09-14 | ||
| PCT/US2012/062042 WO2013063346A1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017109327A Division JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532412A JP2014532412A (ja) | 2014-12-08 |
| JP2014532412A5 true JP2014532412A5 (cg-RX-API-DMAC7.html) | 2015-12-17 |
| JP6154391B2 JP6154391B2 (ja) | 2017-06-28 |
Family
ID=47178940
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539029A Active JP6154391B2 (ja) | 2011-10-28 | 2012-10-26 | 遺伝子改変された主要組織適合複合体マウス |
| JP2017109327A Active JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
| JP2019019707A Active JP6866409B2 (ja) | 2011-10-28 | 2019-02-06 | 遺伝子改変された主要組織適合複合体マウス |
| JP2020081774A Withdrawn JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017109327A Active JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
| JP2019019707A Active JP6866409B2 (ja) | 2011-10-28 | 2019-02-06 | 遺伝子改変された主要組織適合複合体マウス |
| JP2020081774A Withdrawn JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Country Status (27)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013063556A1 (en) | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| SMT201900429T1 (it) | 2013-02-20 | 2019-09-09 | Regeneron Pharma | Topi esprimenti co-recettori umanizzati linfociti t |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| EP2958937B1 (en) * | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| WO2014164640A1 (en) * | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| DK4269430T3 (da) | 2013-09-23 | 2025-08-18 | Regeneron Pharma | Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen |
| SI3138397T1 (sl) | 2013-10-15 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | Humanizirane živali IL-15 |
| CN105578876B (zh) * | 2013-10-18 | 2018-07-13 | 大鹏药品工业株式会社 | 制备表达hlai类的非人动物的方法 |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| KR102173297B1 (ko) | 2013-11-19 | 2020-11-03 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 증식-유도 리간드 유전자를 가지고 있는 비-인간 동물 |
| ES2794942T3 (es) | 2014-04-08 | 2020-11-19 | Regeneron Pharma | Animales no humanos que tienen receptores Fc-gamma humanizados |
| JP6598798B2 (ja) | 2014-05-05 | 2019-10-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｃ５およびｃ３動物 |
| NO2785538T3 (cg-RX-API-DMAC7.html) | 2014-05-07 | 2018-08-04 | ||
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| JP2017529841A (ja) | 2014-09-19 | 2017-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キメラ抗原受容体 |
| RS63410B1 (sr) | 2014-11-24 | 2022-08-31 | Regeneron Pharma | Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks |
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
| LT3230320T (lt) * | 2014-12-09 | 2021-01-11 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| DK3280257T3 (da) | 2015-04-06 | 2023-09-04 | Regeneron Pharma | Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr |
| PT3282835T (pt) * | 2015-04-13 | 2023-07-25 | Univ Yale | Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos |
| LT3376857T (lt) | 2015-11-20 | 2021-06-25 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| EP3462853B1 (en) | 2016-06-03 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| KR102696334B1 (ko) | 2017-09-29 | 2024-08-21 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 C1q 복합체를 발현하는 비인간 동물 |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| AU2018375796B2 (en) | 2017-11-30 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TRKB locus |
| HUE070158T2 (hu) * | 2018-03-24 | 2025-05-28 | Regeneron Pharma | Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk |
| AU2019242586B2 (en) | 2018-03-26 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| PL3823443T3 (pl) | 2018-07-16 | 2024-09-23 | Regeneron Pharmaceuticals, Inc. | Modele gryzoni z chorobą ditra i ich zastosowania |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| BR112021018788A2 (pt) * | 2019-03-25 | 2021-11-23 | Xenotherapeutics Corp | Células, tecidos e órgãos personalizados para transplante de um doador (não humano) humanizado, indivi-dualizado, designado livre de patógenos e métodos e produtos relacionados aos mesmos |
| IL286905B2 (en) | 2019-04-04 | 2024-06-01 | Regeneron Pharma | Non-human animals containing the human coagulation factor 12 locus |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| SG11202111256XA (en) | 2019-06-07 | 2021-11-29 | Regeneron Pharma | Non-human animals comprising a humanized albumin locus |
| EP4087392A4 (en) * | 2020-01-10 | 2024-02-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC MHC PROTEIN COMPLEX |
| WO2022133155A1 (en) * | 2020-12-16 | 2022-06-23 | Xenotherapeutics, Inc. | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs |
| CN116848254A (zh) | 2020-12-16 | 2023-10-03 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
| AU2022249328A1 (en) | 2021-03-31 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire |
| EP4536836A1 (en) | 2022-06-07 | 2025-04-16 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| KR20250035053A (ko) | 2022-06-07 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도 |
| KR20250077529A (ko) | 2022-09-22 | 2025-05-30 | 리제너론 파아마슈티컬스, 인크. | 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스 |
| WO2024159071A1 (en) | 2023-01-27 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
| TW202520975A (zh) * | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| WO2025064470A1 (en) | 2023-09-19 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Viral peptides and uses thereof |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025136809A2 (en) | 2023-12-19 | 2025-06-26 | Regeneron Pharmaceuticals, Inc. | Foxp3 peptides and uses thereof |
| WO2025178991A1 (en) | 2024-02-21 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Splicing factor gene mutation-associated neoantigenic peptides and uses thereof |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| AU633958B2 (en) | 1989-07-25 | 1993-02-11 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | Transgenic non-human animals having targeted lymphocyte transduction genes. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| EP0910409A4 (en) | 1996-03-05 | 2003-03-19 | Scripps Research Inst | RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| AU752590B2 (en) * | 1998-02-17 | 2002-09-26 | Ortho-Mcneil Pharmaceutical, Inc. | H2-O modified transgenic animals |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| WO2001027291A1 (en) * | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| US20030093818A1 (en) | 2000-12-19 | 2003-05-15 | Belmont Heather J. | Transgenic animals comprising a humanized immune system |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| JP4857450B2 (ja) | 2004-03-09 | 2012-01-18 | 財団法人名古屋産業科学研究所 | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
| PL1802193T3 (pl) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej |
| JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
| NZ547859A (en) * | 2006-06-09 | 2009-05-31 | Dec Int Nz Ltd | Treatment method and composition for mastitis |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| EP1878342A1 (en) * | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| CA2685015A1 (en) * | 2007-04-23 | 2008-11-06 | Schering Corporation | Anti-mdl-1 antibodies |
| EP2262898B1 (en) | 2008-03-07 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| EP2153845A1 (en) * | 2008-08-13 | 2010-02-17 | Julius-Maximilians-Universität Würzburg | Endoglin peptides, vaccines and methods for preparing the same |
| EP2517556B2 (en) * | 2009-07-08 | 2023-03-22 | Kymab Limited | Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| SMT201900429T1 (it) | 2013-02-20 | 2019-09-09 | Regeneron Pharma | Topi esprimenti co-recettori umanizzati linfociti t |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| CN105683383B (zh) * | 2013-06-03 | 2020-08-21 | 赛拉福柯蒂斯公司 | 含有I型MHC、II型MHC或β2微球蛋白上游启动子序列的慢病毒载体 |
| CN105578876B (zh) * | 2013-10-18 | 2018-07-13 | 大鹏药品工业株式会社 | 制备表达hlai类的非人动物的方法 |
| DK3280257T3 (da) | 2015-04-06 | 2023-09-04 | Regeneron Pharma | Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr |
-
2012
- 2012-10-26 LT LTEP17184955.7T patent/LT3262932T/lt unknown
- 2012-10-26 CA CA3074400A patent/CA3074400C/en active Active
- 2012-10-26 CN CN201280060540.8A patent/CN104039132B9/zh active Active
- 2012-10-26 MX MX2020010763A patent/MX391222B/es unknown
- 2012-10-26 RS RS20190998A patent/RS59082B1/sr unknown
- 2012-10-26 US US13/661,159 patent/US9615550B2/en active Active
- 2012-10-26 EP EP12787255.4A patent/EP2770821B1/en active Active
- 2012-10-26 RS RS20171195A patent/RS56656B1/sr unknown
- 2012-10-26 MX MX2014004895A patent/MX355725B/es active IP Right Grant
- 2012-10-26 SI SI201231650T patent/SI3262932T1/sl unknown
- 2012-10-26 HR HRP20171761TT patent/HRP20171761T1/hr unknown
- 2012-10-26 KR KR1020147014476A patent/KR101921126B1/ko active Active
- 2012-10-26 SI SI201231136T patent/SI2770821T1/en unknown
- 2012-10-26 EP EP19167619.6A patent/EP3563680B1/en active Active
- 2012-10-26 PT PT127872554T patent/PT2770821T/pt unknown
- 2012-10-26 AU AU2012324016A patent/AU2012324016C1/en active Active
- 2012-10-26 KR KR1020187033187A patent/KR102074145B1/ko active Active
- 2012-10-26 CN CN202110831383.7A patent/CN113564188B/zh active Active
- 2012-10-26 ES ES12787255.4T patent/ES2651517T3/es active Active
- 2012-10-26 SM SM20170576T patent/SMT201700576T1/it unknown
- 2012-10-26 ES ES19167619T patent/ES2962287T3/es active Active
- 2012-10-26 KR KR1020207002887A patent/KR102295746B1/ko active Active
- 2012-10-26 WO PCT/US2012/062042 patent/WO2013063346A1/en not_active Ceased
- 2012-10-26 MX MX2017013466A patent/MX376167B/es unknown
- 2012-10-26 PT PT17184955T patent/PT3262932T/pt unknown
- 2012-10-26 DK DK17184955.7T patent/DK3262932T3/da active
- 2012-10-26 NZ NZ734532A patent/NZ734532A/en unknown
- 2012-10-26 LT LTEP12787255.4T patent/LT2770821T/lt unknown
- 2012-10-26 HU HUE17184955A patent/HUE045879T2/hu unknown
- 2012-10-26 PL PL12787255T patent/PL2770821T3/pl unknown
- 2012-10-26 HU HUE12787255A patent/HUE035652T2/en unknown
- 2012-10-26 EP EP17184955.7A patent/EP3262932B1/en active Active
- 2012-10-26 SM SM20190478T patent/SMT201900478T1/it unknown
- 2012-10-26 ES ES17184955T patent/ES2741649T3/es active Active
- 2012-10-26 SG SG11201400933VA patent/SG11201400933VA/en unknown
- 2012-10-26 CA CA2850387A patent/CA2850387A1/en active Pending
- 2012-10-26 PL PL17184955T patent/PL3262932T3/pl unknown
- 2012-10-26 SG SG10201603188SA patent/SG10201603188SA/en unknown
- 2012-10-26 MY MYPI2017703836A patent/MY178723A/en unknown
- 2012-10-26 MY MYPI2014000784A patent/MY164836A/en unknown
- 2012-10-26 DK DK12787255.4T patent/DK2770821T3/da active
- 2012-10-26 EP EP23193595.8A patent/EP4311833A3/en active Pending
- 2012-10-26 BR BR112014009259-1A patent/BR112014009259A2/pt not_active Application Discontinuation
- 2012-10-26 JP JP2014539029A patent/JP6154391B2/ja active Active
- 2012-10-26 CN CN201710347715.8A patent/CN107254480B/zh active Active
-
2014
- 2014-04-13 IL IL232097A patent/IL232097A/en active IP Right Grant
- 2014-04-25 ZA ZA2014/03085A patent/ZA201403085B/en unknown
-
2016
- 2016-04-27 AU AU2016202688A patent/AU2016202688B2/en active Active
-
2017
- 2017-02-22 US US15/439,828 patent/US10869466B2/en active Active
- 2017-04-30 IL IL252022A patent/IL252022A0/en active IP Right Grant
- 2017-06-01 JP JP2017109327A patent/JP6574457B2/ja active Active
- 2017-11-22 CY CY20171101223T patent/CY1119657T1/el unknown
- 2017-12-22 AU AU2017279797A patent/AU2017279797C1/en active Active
-
2018
- 2018-06-29 HK HK18108466.8A patent/HK1249712B/en unknown
- 2018-08-20 IL IL26123918A patent/IL261239B/en active IP Right Grant
-
2019
- 2019-02-06 JP JP2019019707A patent/JP6866409B2/ja active Active
- 2019-08-06 HR HRP20191420 patent/HRP20191420T1/hr unknown
- 2019-08-07 CY CY20191100840T patent/CY1121869T1/el unknown
-
2020
- 2020-05-07 JP JP2020081774A patent/JP2020146041A/ja not_active Withdrawn
- 2020-08-12 US US16/991,283 patent/US20200375160A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532412A5 (cg-RX-API-DMAC7.html) | ||
| JP7261772B2 (ja) | ヒト化ｔ細胞補助受容体を発現するマウス | |
| JP2023174872A (ja) | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 | |
| JP6574457B2 (ja) | 遺伝子改変された主要組織適合複合体マウス | |
| JP2016510998A5 (cg-RX-API-DMAC7.html) | ||
| CN110192541B (zh) | 表达人源化主要组织相容性复合物的小鼠 | |
| AU2020204410C1 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules | |
| JP2018126170A5 (cg-RX-API-DMAC7.html) | ||
| JP2018513683A5 (cg-RX-API-DMAC7.html) | ||
| JP6456350B2 (ja) | キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス | |
| HRP20220616T1 (hr) | Genetski modificirani miš koji eksprimira kimerne molekule glavnog kompleksa histokompatibilnosti (mhc) ii | |
| KR20250077529A (ko) | 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스 | |
| RU2018112307A (ru) | Генетически модифицированные в отношении главного комплекса гистосовместимости мыши | |
| HK40092669A (en) | Humanized t cell mediated immune responses in non-human animals | |
| BR122019026475B1 (pt) | Composição e método para produzir um camundongo geneticamente modificado |